PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
コンテンツは NeurologyLive® Mind Moments® によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、NeurologyLive® Mind Moments® またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
102: Potential of Gamma Sensory Stimulation in Alzheimer Disease
Manage episode 384305349 series 3340456
コンテンツは NeurologyLive® Mind Moments® によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、NeurologyLive® Mind Moments® またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.
Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.
Episode Breakdown:
In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.
Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.
Episode Breakdown:
- 1:10 – Overview of phase 2 OVERTURE study
- 4:45 – Mechanism of action of gamma sensory stimulation
- 10:00 – Potential therapeutic crossover with emerging treatments
- 12:30 – Neurology News Minute
- 14:50 – Feasibility of the stimulation device
- 18:20– Future plans and planned phase 3 study
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
ATA188 Fails to Meet Primary End Point In Phase 2 EMBOLD Study of Progressive MS
Elecsys Neurofilament Light Test Gains Breakthrough Device Designation as Way to Track MS Disease Activity
FDA Clears Phase 2 Study of CAR T-Cell Therapy KYV-101 in Myasthenia Gravis
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
129 つのエピソード
Manage episode 384305349 series 3340456
コンテンツは NeurologyLive® Mind Moments® によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、NeurologyLive® Mind Moments® またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.
Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.
Episode Breakdown:
In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.
Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.
Episode Breakdown:
- 1:10 – Overview of phase 2 OVERTURE study
- 4:45 – Mechanism of action of gamma sensory stimulation
- 10:00 – Potential therapeutic crossover with emerging treatments
- 12:30 – Neurology News Minute
- 14:50 – Feasibility of the stimulation device
- 18:20– Future plans and planned phase 3 study
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
ATA188 Fails to Meet Primary End Point In Phase 2 EMBOLD Study of Progressive MS
Elecsys Neurofilament Light Test Gains Breakthrough Device Designation as Way to Track MS Disease Activity
FDA Clears Phase 2 Study of CAR T-Cell Therapy KYV-101 in Myasthenia Gravis
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
129 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。